Vascular risk factors and diabetic neuropathy
- PMID: 15673800
- DOI: 10.1056/NEJMoa032782
Vascular risk factors and diabetic neuropathy
Abstract
Background: Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study.
Methods: Neuropathy was assessed at baseline (1989 to 1991) and at follow-up (1997 to 1999), with a mean (+/-SD) follow-up of 7.3+/-0.6 years. A standardized protocol included clinical evaluation, quantitative sensory testing, and autonomic-function tests. Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excretion rate were measured in a central laboratory.
Results: At follow-up, neuropathy had developed in 276 of 1172 patients without neuropathy at baseline (23.5 percent). The cumulative incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabetes. After adjustment for these factors, we found that higher levels of total and low-density lipoprotein cholesterol and triglycerides, a higher body-mass index, higher von Willebrand factor levels and urinary albumin excretion rate, hypertension, and smoking were all significantly associated with the cumulative incidence of neuropathy. After adjustment for other risk factors and diabetic complications, we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up period, body-mass index, and smoking remained independently associated with the incidence of neuropathy. Cardiovascular disease at baseline was associated with double the risk of neuropathy, independent of cardiovascular risk factors.
Conclusions: This prospective study indicates that, apart from glycemic control, the incidence of neuropathy is associated with potentially modifiable cardiovascular risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
Early vascular risk factor modification in type 1 diabetes.N Engl J Med. 2005 Jan 27;352(4):408-9. doi: 10.1056/NEJMe048340. N Engl J Med. 2005. PMID: 15673807 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. doi: 10.1056/NEJM200505053521817. N Engl J Med. 2005. PMID: 15872210 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. N Engl J Med. 2005. PMID: 15877320 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. N Engl J Med. 2005. PMID: 15877321 No abstract available.
Similar articles
-
Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.Diabetologia. 1997 Jun;40(6):698-705. doi: 10.1007/s001250050736. Diabetologia. 1997. PMID: 9222650
-
Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.Diab Vasc Dis Res. 2018 Sep;15(5):424-432. doi: 10.1177/1479164118780808. Epub 2018 Jun 18. Diab Vasc Dis Res. 2018. PMID: 29911415
-
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.Am J Epidemiol. 1999 Dec 1;150(11):1142-51. doi: 10.1093/oxfordjournals.aje.a009941. Am J Epidemiol. 1999. PMID: 10588075
-
Modifiable vascular risk factors are associated with diabetic neuropathy in type 1 diabetes.Postgrad Med. 2005 Apr;117(4):7. doi: 10.3810/pgm.2005.04.1811. Postgrad Med. 2005. PMID: 15842127 Review. No abstract available.
-
The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?Curr Diab Rep. 2009 Dec;9(6):432-4. doi: 10.1007/s11892-009-0070-1. Curr Diab Rep. 2009. PMID: 19954687 Review.
Cited by
-
Assessing the diagnostic utility of urinary albumin-to-creatinine ratio as a potential biomarker for diabetic peripheral neuropathy in type 2 diabetes mellitus patients.Sci Rep. 2024 Nov 8;14(1):27198. doi: 10.1038/s41598-024-78828-y. Sci Rep. 2024. PMID: 39516711 Free PMC article.
-
Genetic studies of type 2 diabetes, and microvascular complications of diabetes.Diabetol Int. 2024 May 13;15(4):699-706. doi: 10.1007/s13340-024-00727-4. eCollection 2024 Oct. Diabetol Int. 2024. PMID: 39469559 Review.
-
Corneal nerve loss in adolescents with obesity and acanthosis nigricans.PLoS One. 2024 Oct 21;19(10):e0309761. doi: 10.1371/journal.pone.0309761. eCollection 2024. PLoS One. 2024. PMID: 39432507 Free PMC article.
-
Promising predictors of diabetic peripheral neuropathy in children and adolescents with type 1 diabetes mellitus.Ital J Pediatr. 2024 Oct 14;50(1):215. doi: 10.1186/s13052-024-01774-y. Ital J Pediatr. 2024. PMID: 39402605 Free PMC article.
-
Objective Analysis of Traditional Chinese Medicine Syndrome Differentiation of Patients With Diabetes and Prediabetes: Protocol for a Nonrandomized, Exploratory, Observational Case-Control Study Using Digitalized Traditional Chinese Medicine Diagnostic Tools.JMIR Res Protoc. 2024 Sep 12;13:e56024. doi: 10.2196/56024. JMIR Res Protoc. 2024. PMID: 39265161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical